Eli Lilly is reducing the cash prices of single-dose vials of its weight loss drug Zepbound on LillyDirect, making it more affordable for cash-paying patients with valid prescriptions. The starting dose is now $299 per month, down from $349, with other doses also seeing price decreases. Zepbound has a list price of $1,086 per month.

This move by Eli Lilly follows similar efforts by Novo Nordisk to offer discounts on the cash prices of its obesity and diabetes drugs. President Donald Trump recently negotiated deals with both companies to improve access to GLP-1 drugs. Eli Lilly’s agreement involves lowering prices on a different form of Zepbound after FDA approval.

Eli Lilly’s decision to lower prices on single-dose vials of Zepbound could help more patients access discounted treatments quickly. Direct-to-consumer sales of Zepbound account for over a third of new prescriptions, showing the significance of this move. The company is committed to expanding options for delivery devices and pathways for access to essential medicines.

Read more at CNBC: Eli Lilly cuts cash prices of Zepbound weight loss drug vials